Menu

1 / 2

AbbVie's Growth Engine Is Firing On All Cylinders

Seeking Alpha·Gen Alpha·6 months ago
#9zGL6gPz
#source#chevron#alpha#investment#growth
Reading 0:00
15s threshold

Home

Stock Ideas

Long Ideas

Healthcare

Summary

AbbVie is a compelling 'Buy' as it has strong momentum in existing drugs and has a robust pipeline.

Robust Q1 2026 results: net revenue up 12.4% YoY, driven by Immunology (Skyrizi +29%, Rinvoq +20%) and Neuroscience (+24%).

Management raised 2026 EPS guidance to $14.18, signaling 42% YoY growth and confidence in ABBV’s diversified growth drivers and pipeline.

With a 3.4% yield, strong balance sheet, and double-digit EPS growth outlook, ABBV is rated ‘Buy’ for income and growth-focused investors.

Looking for a portfolio of ideas like this one? Members of iREIT®+HOYA Capital get exclusive access to our subscriber-only portfolios. Learn More »

PM Images/DigitalVision via Getty Images

Not every stock has to be a slam dunk investment. Rather, it helps to put an owner’s hat on whenever one buys a stock with a durable track record.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.